Japan's largest pharmaceutical company, Takeda, will present data on various products within its hematology-oncology line of products during the American Society of Hematology's (ASH) annual meeting taking place Dec. 5 to Dec. 8 in Orlando, Florida.
Data from a Phase 3 TOURMALINE-MM1 clinical trial of ixazomib in the treatment of adult patients with relapsed and/or refractory multiple myeloma will be presented in an oral presentation on Monday, Dec. 7. Multiple myeloma is a cancer that develops in plasma cells, a type of white blood cell, which can result in a weakened immune system, kidney problems, anemia and bone fracture.
Ixazomib, taken orally, is a proteasome inhibitor that disrupts cancer cells' ability to grow and survive. The drug is the first oral proteasome inhibitor to be in late-stage clinical development and has been given Priority Review from the U.S. Food and Drug Administration.
“In working with Takeda Oncology on the evolution of proteasome inhibition, we continue to strive toward providing new options to address the unmet needs of patients with multiple myeloma,” Philippe Moreau, the principal investigator of the Tourmaline-MM1 study, said.
Other presentations will include a poster session featuring five-year overall survival data for Adcetris (brentuximab vedotin) in individuals with relapsed or refractory Hodgkin lymphoma as well as an oral presentation on Velcade (bortezomib) in patients with untreated non-germinal center B-cell-like subtype diffuse large cell lymphoma (DLBCL).